Orexo AB(ORX)

Description: Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.

---

Keywords: Pharmaceutical Cancer Drugs Pain Organic Compounds Psychiatric Diagnosis Opioids Morphinans Opioid Use Disorder Naloxone Breakthrough Pain Opioid Antagonists Allergic Reactions Buprenorphine/Naloxone Ketorolac Abstral Chronic Inflammatory Conditions Edluar Microvascular Diseases Nalmefene Severe Depression Short Term Insomnia Tertiary Alcohols Treatment Of Breakthrough Pain In Cancer Treatment Of Microvascular Diseases Zubsolv

---

Home Page: www.orexo.com

P.O. Box 303
Uppsala, 751 05
Sweden
Phone: 46 1 87 80 88 00

---

Officers

Exchange: ST

Country: SE

Currency: Swedish krone (kr)